Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

<p>A proposed model of ATRi resistance caused by SMG8/9 loss of function.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Marta J. Llorca-Cardenosa (14961612) (author)
Andere auteurs:	Lauren I. Aronson (14961615) (author), Dragomir B. Krastev (14961618) (author), Jadwiga Nieminuszczy (14961621) (author), John Alexander (14961624) (author), Feifei Song (14961627) (author), Malgorzata Dylewska (14961630) (author), Ronan Broderick (14961633) (author), Rachel Brough (14961636) (author), Astrid Zimmermann (14961639) (author), Frank T. Zenke (14961642) (author), Bora Gurel (14961645) (author), Ruth Riisnaes (14961648) (author), Ana Ferreira (14961651) (author), Theodoros Roumeliotis (14961654) (author), Jyoti Choudhary (14961657) (author), Stephen J. Pettitt (14952601) (author), Johann de Bono (14961660) (author), Andres Cervantes (14961663) (author), Syed Haider (14961666) (author), Wojciech Niedzwiedz (14961669) (author), Christopher J. Lord (14952616) (author), Irene Y. Chong (14961672) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Molecular and Cellular Biology Therapeutic Research and Development DNA Damage and Repair DNA repair Drug Mechanisms Drug Resistance Gastrointestinal Cancers Stomach cancer
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
door: Marta J. Llorca-Cardenosa (14961612)
Gepubliceerd in: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
door: Marta J. Llorca-Cardenosa (14961612)
Gepubliceerd in: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
door: Marta J. Llorca-Cardenosa (14961612)
Gepubliceerd in: (2025)

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
door: Marta J. Llorca-Cardenosa (14961612)
Gepubliceerd in: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
door: Arun Kanakkanthara (14937731)
Gepubliceerd in: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
door: Arun Kanakkanthara (14937731)
Gepubliceerd in: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
door: Long Jiang (14956159)
Gepubliceerd in: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
door: Long Jiang (14956159)
Gepubliceerd in: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
door: Long Jiang (14956159)
Gepubliceerd in: (2025)

Supplementary Figure S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
door: Kavya Ramkumar (16474203)
Gepubliceerd in: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
door: Min Wei (16918572)
Gepubliceerd in: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
door: Min Wei (16918572)
Gepubliceerd in: (2025)

Supplementary Figure 9 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
door: Biagio Ricciuti (14951247)
Gepubliceerd in: (2025)

Supplementary Figure S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S14 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S15 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S16 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S17 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S18 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S19 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S2 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S20 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S21 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S6 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_irc9i1m9i31qsquuvmhhjpk1d5